Author

Hennig Wege

Observed names: H. Wege, Wege, H.

Institution: University Medical Center Hamburg-Eppendorf

Observed institution: University Medical Center Hamburg-Eppendorf

OpenAlex ID: A5090004161

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

2019 · M. Moehler, J. Heo, et al. · OncoImmunology · 137

TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial

2014 · Andreas Erhardt, Frank Kolligs, et al. · Cancer Chemotherapy and Pharmacology · 70

53MO Nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116)

2022 · A. Vogel, P. Wenzel, et al. · Annals of Oncology · 34

Adjuvant chemotherapy with cisplatin and gemcitabine compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial)

2026 · A. Stein, J. Bridgewater, et al. · Annals of Oncology

2015 · Vogel, A., Wege, H., et al. · RWTH Publications (RWTH Aachen)

Works count: 7

Citation count: 241

H-index: 3

I10-index: 3